Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities

• Published in: Cancer discovery Vol. 10; no. 12; pp. 1950 - 1967
• Main Authors: Kelly, Marcus R, Kostyrko, Kaja, Han, Kyuho, Mooney, Nancie A, Jeng, Edwin E, Spees, Kaitlyn, Dinh, Phuong T, Abbott, Keene L, Gwinn, Dana M, Sweet-Cordero, E Alejandro, Bassik, Michael C, Jackson, Peter K
• Format: Journal Article
• Language: English
• Published: United States 01.12.2020
• Subjects: Humans; Lung Neoplasms - genetics; Proteomics - methods; ras Proteins - genetics
• ISSN: 2159-8274; 2159-8290
• DOI: 10.1158/2159-8290.CD-19-1274

Activating mutations in RAS GTPases drive many cancers, but limited understanding of less-studied RAS interactors, and of the specific roles of different RAS interactor paralogs, continues to limit target discovery. We developed a multistage discovery and screening process to systematically identify genes conferring RAS-related susceptibilities in lung adenocarcinoma. Using affinity purification mass spectrometry, we generated a protein-protein interaction map of RAS interactors and pathway components containing hundreds of interactions. From this network, we constructed a CRISPR dual knockout library targeting 119 RAS-related genes that we screened for -dependent genetic interactions (GI). This approach identified new RAS effectors, including the adhesion controller RADIL and the endocytosis regulator RIN1, and >250 synthetic lethal GIs, including a potent -dependent interaction between and Many GIs link specific paralogs within and between gene families. These findings illustrate the power of multiomic approaches to uncover synthetic lethal combinations specific for hitherto untreatable cancer genotypes. SIGNIFICANCE: We establish a deep network of protein-protein and genetic interactions in the RAS pathway. Many interactions validated here demonstrate important specificities and redundancies among paralogous RAS regulators and effectors. By comparing synthetic lethal interactions across -dependent and -independent cell lines, we identify several new combination therapy targets for RAS-driven cancers. .